Avantor, Inc. (NYSE:AVTR) posted fourth-quarter results on Wednesday that met Wall Street expectations, but the update did little to reassure investors about the progress of its restructuring plan.
Shares of the life sciences tools provider declined 5.6% in premarket trading following the announcement.
The company reported adjusted earnings per share of $0.22, in line with analyst forecasts. Revenue totaled $1.66 billion, slightly above the $1.64 billion consensus estimate. However, sales were down 1.4% from a year earlier, while organic revenue declined 4.1% after excluding currency movements and acquisition-related impacts.
“Through the Revival program we initiated last quarter, we are building a more agile company that is better organized around the needs of our customers,” said Emmanuel Ligner, President and Chief Executive Officer. “We are moving with urgency to execute Revival and turn around the performance of this great business.”
Performance was weak across key segments. The Laboratory Solutions division, which generates roughly two-thirds of total revenue, posted a 4.1% year-over-year decline in organic sales. The Bioscience Production unit also recorded a 4.1% drop in organic revenue.
Adjusted EBITDA came in at $252 million, with margin narrowing to 15.2% from 18.2% in the same quarter last year, underscoring ongoing profitability pressures as the company advances its restructuring initiatives.
For full-year 2025, Avantor reported net sales of $6.55 billion, down 3.4% compared with 2024, while organic sales fell 2.8%. The company recorded a net loss of $530 million, reversing a net profit of $712 million in the prior year, largely due to impairment charges.
Management described 2026 as “a year of transition and purposeful investment,” emphasizing efforts to reignite revenue growth and reinforce its competitive position.